Steven Cohen Merus N.V. Transaction History

Point72 Asset Management, L.P.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$28.03 - $51.82 $308,554 - $570,434	11,008 New	11,008 $495,000
Q3 2023 Nov 14, 2023	SELL	$20.13 - $27.29 $8.57 Million - $11.6 Million	-425,803 Reduced 69.9%	183,394 $4.32 Million
Q2 2023 Aug 14, 2023	BUY	$18.33 - $27.18 $7.6 Million - $11.3 Million	414,737 Added 213.28%	609,197 $16 Million
Q1 2023 May 15, 2023	BUY	$14.25 - $20.5 $2.77 Million - $3.99 Million	194,460 New	194,460 $3.58 Million
Q2 2022 Aug 15, 2022	BUY	$13.98 - $29.25 $3.83 Million - $8 Million	273,609 Added 224.93%	395,250 $8.95 Million
Q1 2022 May 16, 2022	BUY	$23.58 - $30.91 $16,506 - $21,637	700 Added 0.58%	121,641 $3.22 Million
Q4 2021 Feb 14, 2022	SELL	$20.0 - $32.29 $864,180 - $1.4 Million	-43,209 Reduced 26.32%	120,941 $3.85 Million
Q3 2021 Nov 15, 2021	SELL	$16.48 - $27.23 $1,648 - $2,723	-100 Reduced 0.06%	164,150 $3.61 Million
Q2 2021 Aug 16, 2021	BUY	$20.0 - $25.48 $3.29 Million - $4.19 Million	164,250 New	164,250 $3.46 Million

200

61.9M

243K

300K

Ticker MRUS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,878,200
Market Cap $1.92B
Description
Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase...

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.